methyl 4-[3-amino-5-chloro-3-(2-chlorophenyl)-2,3-dihydro-2-oxoindol-1-yl]methyl-3-methoxybenzoate | 169040-12-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 4-[3-amino-5-chloro-3-(2-chlorophenyl)-2,3-dihydro-2-oxoindol-1-yl]methyl-3-methoxybenzoate
• 英文别名: methyl 4-[[3-amino-5-chloro-3-(2-chlorophenyl)-2-oxoindol-1-yl]methyl]-3-methoxybenzoate
• CAS: 169040-12-4
• 化学式: C₂₄H₂₀Cl₂N₂O₄
• 分子量: 471.34
• InChiKey: ZYOJRFGCUHZEQV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  32
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  81.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  丙酰氯 、 methyl 4-[3-amino-5-chloro-3-(2-chlorophenyl)-2,3-dihydro-2-oxoindol-1-yl]methyl-3-methoxybenzoate 在 乙酸乙酯 、 水 、 氯化钠 、 Sodium sulfate-III 、 silica 、 ethyl acetate n-hexane 作用下， 以 吡啶 为溶剂， 反应 24.0h， 以to give 1.3 g of the expected product的产率得到Methyl 4-[[5-chloro-3-(2-chlorophenyl)-2,3-dihydro-2-oxo-3-propionamidoindol-1-yl]methyl]-3-methoxybenzoate
  参考文献：
  名称：

  Indol-2-one derivatives

  摘要：

  化合物II'的化学式为##STR1## 其中R.sub.I为乙氧基或氯原子；R.sub.II为氢、氯原子或甲基基团；R.sub.III为氯苯基或甲氧基苯基；R.sub.IV为氨基、NR.sub.9 R.sub.10或NR.sub.9 R.sub.XI基团，或者在4-位置被取代的哌嗪-1-基基团，所取代的基团为(C.sub.2 -C.sub.10)烷基基团，该基团被氨基自由取代或带有保护基；R.sub.10为(CH.sub.2).sub.p R.sub.35或(C.sub.2 -C.sub.10)烷基基团，该基团被R.sub.21取代；R.sub.XI为(C.sub.1 -C.sub.12)烷基基团或.omega.-R.sub.32 R.sub.33 N(C.sub.1 -C.sub.4)-烷基羰基基团；R.sub.21为R.sub.36、OR.sub.37、NR.sub.32 R.sub.33、氰基、S(C.sub.1 -C.sub.7)烷基、SO(C.sub.1 -C.sub.7)烷基或SO.sub.2 (C.sub.1 -C.sub.7)烷基；R.sub.35为哌啶-4-基基团，该基团未取代或在1-位置被(C.sub.1 -C.sub.7)烷氧羰基基团或(C.sub.1 -C.sub.7)烷基基团取代；或者为吡啶-2-基基团；R.sub.37为R.sub.13、(C.sub.3 -C.sub.7)环烷基团、被R.sub.24取代的(C.sub.1 -C.sub.6)烷基基团、被羟基或(C.sub.1 -C.sub.7)烷氧基取代的(C.sub.2 -C.sub.6)烷基基团；或者被自由氨基或被一或两个(C.sub.1 -C.sub.7)烷基或保护基取代的(C.sub.2 -C.sub.6)烷基基团；R.sub.24为羧基、(C.sub.1 -C.sub.7)烷氧羰基、苄氧羰基或自由或被一或两个(C.sub.1 -C.sub.7)烷基取代的氨基基团。

  公开号：

  US05773612A1
• 作为产物：
  描述：

  3-Amino-5-chloro-3-(2-chlorophenyl)-1,3-di-hydroindol-2-one 、 4-溴甲基-3-甲氧基苯甲酸甲酯 、 4-(dicyanomethylene)-2-methyl-6-(p-dimethylaminostyryl)-4H-pyran 以 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 生成 methyl 4-[3-amino-5-chloro-3-(2-chlorophenyl)-2,3-dihydro-2-oxoindol-1-yl]methyl-3-methoxybenzoate
  参考文献：
  名称：

  1,3-dihydroindol-2-one derivatives substituted in the 3-position by a

  摘要：

  本发明涉及式(I)化合物及其盐，如适用：这些化合物具有对加压素和/或催产素受体的亲和力。

  公开号：

  US05594023A1

文献信息

• US5594023A
  申请人：——

  公开号：US5594023A

  公开（公告）日：1997-01-14
• 1,3-dihydroindol-2-one derivatives substituted in the 3-position by a
  申请人：Sanofi

  公开号：US05594023A1

  公开（公告）日：1997-01-14

  The present invention relates to compounds of formula (I) and salts thereof, where appropriate: ##STR1## These compounds have an affinity for the vasopressin and/or ocytocin receptors.

  本发明涉及式(I)化合物及其盐，如适用：这些化合物具有对加压素和/或催产素受体的亲和力。
• Indol-2-one derivatives
  申请人：Sanofi

  公开号：US05773612A1

  公开（公告）日：1998-06-30

  A compound of formula II' ##STR1## in which R.sub.I is an ethoxy group or a chlorine atom; R.sub.II is hydrogen, a chlorine atom or a methyl group; R.sub.III is a chlorophenyl group or a methoxyphenyl group; R.sub.IV is an amino group, a group NR.sub.9 R.sub.10 or NR.sub.9 R.sub.XI, or a piperazin-1-yl radical substituted in the 4-position by a (C.sub.2 -C.sub.10)alkylene group substituted by an amino group which is free or carries a protective group; R.sub.10 is (CH.sub.2).sub.p R.sub.35 or a (C.sub.2 -C.sub.10)alkylene group substituted by R.sub.21 ; R.sub.XI is a (C.sub.1 -C.sub.12)alkyl group or a group .omega.-R.sub.32 R.sub.33 N(C.sub.1 -C.sub.4)-alkylcarbonyl; and R.sub.21 is R.sub.36 ; a group OR.sub.37 ; a group NR.sub.32 R.sub.33 ; a cyano group; a group S(C.sub.1 -C.sub.7)alkyl; a group SO(C.sub.1 -C.sub.7)alkyl; or a group SO.sub.2 (C.sub.1 -C.sub.7)alkyl; R.sub.35 is a piperid-4-yl group which is unsubstituted or substituted in the 1-position by a (C.sub.1 -C.sub.7)alkoxycarbonyl group or by a (C.sub.1 -C.sub.7)alkyl group; or a pyrid-2-yl group; R.sub.37 is R.sub.13 ; a (C.sub.3 -C.sub.7)cycloalkyl group; a (C.sub.1 -C.sub.6)alkylene group substituted by R.sub.24 ; a (C.sub.2 -C.sub.6)alkylene group substituted by a hydroxyl or a (C.sub.1 -C.sub.7)alkoxy group; or a (C.sub.2 -C.sub.6)alkylene group substituted by an amino group which is free or substituted by one or two (C.sub.1 -C.sub.7)alkyl groups or by a protective group; R.sub.24 is a carboxyl group; a (C.sub.1 -C.sub.7)alkoxycarbonyl group; a benzyloxycarbonyl group; or a carbamoyl group which is free or substituted by one or two (C.sub.1 -C.sub.7)alkyl groups.

  化合物II'的化学式为##STR1## 其中R.sub.I为乙氧基或氯原子；R.sub.II为氢、氯原子或甲基基团；R.sub.III为氯苯基或甲氧基苯基；R.sub.IV为氨基、NR.sub.9 R.sub.10或NR.sub.9 R.sub.XI基团，或者在4-位置被取代的哌嗪-1-基基团，所取代的基团为(C.sub.2 -C.sub.10)烷基基团，该基团被氨基自由取代或带有保护基；R.sub.10为(CH.sub.2).sub.p R.sub.35或(C.sub.2 -C.sub.10)烷基基团，该基团被R.sub.21取代；R.sub.XI为(C.sub.1 -C.sub.12)烷基基团或.omega.-R.sub.32 R.sub.33 N(C.sub.1 -C.sub.4)-烷基羰基基团；R.sub.21为R.sub.36、OR.sub.37、NR.sub.32 R.sub.33、氰基、S(C.sub.1 -C.sub.7)烷基、SO(C.sub.1 -C.sub.7)烷基或SO.sub.2 (C.sub.1 -C.sub.7)烷基；R.sub.35为哌啶-4-基基团，该基团未取代或在1-位置被(C.sub.1 -C.sub.7)烷氧羰基基团或(C.sub.1 -C.sub.7)烷基基团取代；或者为吡啶-2-基基团；R.sub.37为R.sub.13、(C.sub.3 -C.sub.7)环烷基团、被R.sub.24取代的(C.sub.1 -C.sub.6)烷基基团、被羟基或(C.sub.1 -C.sub.7)烷氧基取代的(C.sub.2 -C.sub.6)烷基基团；或者被自由氨基或被一或两个(C.sub.1 -C.sub.7)烷基或保护基取代的(C.sub.2 -C.sub.6)烷基基团；R.sub.24为羧基、(C.sub.1 -C.sub.7)烷氧羰基、苄氧羰基或自由或被一或两个(C.sub.1 -C.sub.7)烷基取代的氨基基团。